Class information for:
Level 1: CHRONIC HEPATITIS B//ENTECAVIR//LAMIVUDINE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
224 3815 37.1 87%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
124 23152 HEPATITIS B VIRUS//CHRONIC HEPATITIS B//HEPATITIS B

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CHRONIC HEPATITIS B Author keyword 424 45% 19% 720
2 ENTECAVIR Author keyword 375 70% 8% 310
3 LAMIVUDINE Author keyword 339 43% 16% 605
4 ADEFOVIR Author keyword 167 61% 5% 175
5 ADEFOVIR DIPIVOXIL Author keyword 128 66% 3% 117
6 TELBIVUDINE Author keyword 112 70% 2% 93
7 LAMIVUDINE RESISTANCE Author keyword 95 84% 1% 52
8 HEPATITIS B VIRUS Author keyword 89 13% 17% 660
9 HBEAG SEROCONVERSION Author keyword 63 76% 1% 44
10 NUCLEOSTIDE ANALOGUES Author keyword 60 75% 1% 44

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CHRONIC HEPATITIS B 424 45% 19% 720 Search CHRONIC+HEPATITIS+B Search CHRONIC+HEPATITIS+B
2 ENTECAVIR 375 70% 8% 310 Search ENTECAVIR Search ENTECAVIR
3 LAMIVUDINE 339 43% 16% 605 Search LAMIVUDINE Search LAMIVUDINE
4 ADEFOVIR 167 61% 5% 175 Search ADEFOVIR Search ADEFOVIR
5 ADEFOVIR DIPIVOXIL 128 66% 3% 117 Search ADEFOVIR+DIPIVOXIL Search ADEFOVIR+DIPIVOXIL
6 TELBIVUDINE 112 70% 2% 93 Search TELBIVUDINE Search TELBIVUDINE
7 LAMIVUDINE RESISTANCE 95 84% 1% 52 Search LAMIVUDINE+RESISTANCE Search LAMIVUDINE+RESISTANCE
8 HEPATITIS B VIRUS 89 13% 17% 660 Search HEPATITIS+B+VIRUS Search HEPATITIS+B+VIRUS
9 HBEAG SEROCONVERSION 63 76% 1% 44 Search HBEAG+SEROCONVERSION Search HBEAG+SEROCONVERSION
10 NUCLEOSTIDE ANALOGUES 60 75% 1% 44 Search NUCLEOSTIDE+ANALOGUES Search NUCLEOSTIDE+ANALOGUES

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ADEFOVIR DIPIVOXIL 698 66% 17% 652
2 LAMIVUDINE THERAPY 358 60% 10% 387
3 E ANTIGEN SEROCONVERSION 298 71% 6% 243
4 ENTECAVIR 247 65% 6% 234
5 LAMIVUDINE 242 27% 20% 759
6 LONG TERM LAMIVUDINE 201 90% 2% 88
7 LAMIVUDINE TREATMENT 183 56% 6% 226
8 YMDD MOTIF 178 84% 3% 98
9 E ANTIGEN 168 33% 11% 414
10 DIPIVOXIL 166 75% 3% 119

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HEPATOLOGY INTERNATIONAL 10 13% 2% 68

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Chronic hepatitis B 2007 1301 233 65%
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update 2008 440 98 80%
Drug therapy - Hepatitis B virus infection 2008 376 98 85%
Incidence of natural resistance mutations in naive chronic hepatitis B patients: A systematic review and meta-analysis 2015 3 45 89%
Hepatitis B virus infection 2009 383 116 63%
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures 2004 1097 72 53%
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues 2009 206 111 79%
Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy 2013 48 33 70%
HBsAg quantification: useful for monitoring natural history and treatment outcome 2014 11 63 94%
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review 2010 133 40 80%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NKC GASTROENTEROL HEPATOL 20 63% 0.5% 20
2 U271 11 25% 1.0% 38
3 U871 11 29% 0.8% 32
4 NEW ZEALAND LIVER UNIT 8 100% 0.1% 5
5 SONGKLANAGARIND HOSP 8 36% 0.4% 17
6 MED HEPATOL 7 25% 0.7% 25
7 TORONTO WESTERN GEN HOSP 7 57% 0.2% 8
8 HEPATOL UNIT 7 10% 1.6% 60
9 HEPATITIS 7 10% 1.6% 61
10 LIVER DIS HEPATITIS PROGRAM 6 33% 0.4% 16

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000209715 HEPATITIS B VIRUS//PRECORE//PRECORE MUTATION
2 0.0000161965 HEPATITIS B IMMUNOGLOBULIN//HBIG//HEPATITIS B RECURRENCE
3 0.0000123457 HBV REACTIVATION//HEPATITIS B VIRUS REACTIVATION//HEPATITIS B REACTIVATION
4 0.0000121756 PATHOGENESE VIRUS HEPATITE B//WOODCHUCK HEPATITIS VIRUS//WOODCHUCK
5 0.0000111424 IGM ANTI HBC//ANTI HBC IGM//HBVDNA
6 0.0000071380 INTERNAL MED MOL BIOL 2//HEPADNAVIRUS//DUCK HEPATITIS B VIRUS
7 0.0000064265 OCCULT HBV INFECTION//ANTI HBC//OCCULT HEPATITIS B VIRUS INFECTION
8 0.0000056163 HIV HCV CO INFECTION//HIV HCV COINFECTION//COINFECTION
9 0.0000054773 HEPATITIS B VACCINE//HEPATITIS B//HEPATITIS B VACCINATION
10 0.0000048649 HEPATITIS B VIRUS ASSOCIATED GLOMERULONEPHRITIS//HBV ASSOCIATED NEPHROPATHY//HEPATITIS B SURFACE ANTIGENEMIA